Cardax Inc
Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and w… Read more
Cardax Inc (CDXI) - Total Assets
Latest total assets as of March 2021: $1.38 Million USD
Based on the latest financial reports, Cardax Inc (CDXI) holds total assets worth $1.38 Million USD as of March 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Cardax Inc - Total Assets Trend (2011–2020)
This chart illustrates how Cardax Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Cardax Inc - Asset Composition Analysis
Current Asset Composition (December 2020)
Cardax Inc's total assets of $1.38 Million consist of 78.7% current assets and 21.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.4% |
| Accounts Receivable | $3.06K | 0.2% |
| Inventory | $994.32K | 69.8% |
| Property, Plant & Equipment | $962.00 | 0.1% |
| Intangible Assets | $302.41K | 21.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2011–2020)
This chart illustrates how Cardax Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cardax Inc's current assets represent 78.7% of total assets in 2020, an increase from 46.4% in 2011.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2020, down from 37.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 21.0% of total assets, a decrease from 50.0% in 2011.
- Asset Diversification: The largest asset category is inventory at 69.8% of total assets.
Cardax Inc Competitors by Total Assets
Key competitors of Cardax Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Cardax Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Cardax Inc generates 0.38x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Cardax Inc is currently not profitable relative to its asset base.
Cardax Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.09 | 0.17 | 0.11 |
| Quick Ratio | 0.01 | 0.04 | 0.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-11.36 Million | $ -6.93 Million | $ -4.15 Million |
Cardax Inc - Advanced Valuation Insights
This section examines the relationship between Cardax Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -29.4% |
| Total Assets | $1.43 Million |
| Market Capitalization | $59.02 USD |
Valuation Analysis
Below Book Valuation: The market values Cardax Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cardax Inc's assets decreased by 29.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cardax Inc (2011–2020)
The table below shows the annual total assets of Cardax Inc from 2011 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | $1.43 Million | -29.41% |
| 2019-12-31 | $2.02 Million | -17.89% |
| 2018-12-31 | $2.46 Million | -22.11% |
| 2017-12-31 | $3.16 Million | +320.57% |
| 2016-12-31 | $750.58K | -11.91% |
| 2015-12-31 | $852.08K | -44.92% |
| 2014-12-31 | $1.55 Million | -12.52% |
| 2013-12-31 | $1.77 Million | +14110.38% |
| 2012-12-31 | $12.45K | -78.95% |
| 2011-12-31 | $59.12K | -- |